Key Summary Points {#FPar1}
==================

**Why carry out this study?**Invasive meningococcal disease is a life-threatening disease that can mimic mild respiratory illness in the early stages but can rapidly progress to death within 24--48 h.The disease burden and epidemiology of meningococcal disease in India are not reliably known.In this comprehensive review with a systematically conducted literature search, we summarize information on the epidemiology, disease burden and vaccination recommendations for meningococcal disease in India.**What was learned from this study?**In the last 25 years, meningococcal disease has not been limited to the pediatric population (cases were often documented in the adolescent and adult population).Data on the burden of meningococcal disease show that the country is susceptible to outbreaks.Data on the burden of endemic disease remains unreliable because of limited disease surveillance, insufficient laboratory capacity, misdiagnosis and extensive antibiotic use, which is prevalent in India.Outbreaks of meningococcal disease in India are most commonly caused by serogroup A. Other serogroups such as B, C, W and Y have also been reported in the non-outbreak studies.In India, there is no national policy on routine meningococcal vaccination to control the disease.

Introduction {#Sec1}
============

Meningococcal disease caused by the gram-negative bacteria *Neisseria meningitidis* (*N. meningitidis*) is a leading cause of meningitis and highly fatal septicemia globally \[[@CR1], [@CR2]\]. It is an unpredictable disease, which can easily be misdiagnosed at an early stage with non-specific symptoms such as flu-like symptoms. Meningococcal disease is associated with rapid onset, significant risk of death with a high fatality rate (up to 50.0%) in untreated cases and high frequency (10.0--20.0%) of severe sequelae causing brain damage, hearing loss or other such long-term disability \[[@CR3]\]. The bacteria *N. meningitidis* only infect humans and are transmitted from one person to another through droplets of respiratory or throat secretions via carriers through close contacts \[[@CR3]\]. The bacteria can be carried in the upper respiratory tract of humans, and research suggests that 1.0--10.0% of the population carries *N. meningitidis* in their throat at any given time \[[@CR3]\]. Published literature suggests that carriage rates may be higher (up to 90.0%) in epidemic situations and in confined populations such as military recruits and people on pilgrimages \[[@CR4]--[@CR8]\]. Meningococci are categorized into 12 distinct serogroups, of which only 6, namely A, B, C, W-135 (W), X and Y capsular polysaccharides, are known to cause the majority of invasive meningococcal disease globally \[[@CR1], [@CR9], [@CR10]\].

The majority of meningitis cases in India are attributed to serogroup A \[[@CR11]--[@CR15]\], with sporadic cases related to serogroup B and C \[[@CR13]\]. In India, *N. meningitidis* is the third most common cause of bacterial meningitis in children \< 5 years of age and is responsible for 1.9% of all cases regardless of age \[[@CR13]\]. However, meningococcal disease surveillance in India is not routine, and data on endemic disease are lacking because of insufficient disease surveillance systems and limited availability of diagnostic facilities. It is to be noted that the Integrated Disease Surveillance Program (IDSP) does conduct routine disease surveillance, but this information is not part of the public domain; thus, the actual data on disease surveillance remain unknown. According to a recent review, occasional outbreaks have often been reported in India. These outbreaks may be large in magnitude as reported in Delhi between 2002 and 2004, where 971 confirmed cases were reported \[[@CR16]\]. Regardless of outbreak or non-outbreak settings, adolescents and young adults can predominantly be affected \[[@CR15]\]. A higher incidence of meningococcal disease has been reported from the temperate northern regions of the country as opposed to tropical southern India, but incidence estimates are not reliable due to suboptimal surveillance and insufficient microbiologic diagnostic support \[[@CR15]\]. Together these factors may lead to under-reporting and under-representation of the true meningococcal disease burden in India.

In India, due to the lack of surveillance systems, poor reporting and ease of access to the healthcare system, meningococcal disease incidence is perceived to be low, and meningococcal vaccines are not routinely recommended \[[@CR15], [@CR17]\]. It is therefore likely that the real epidemiology and burden of disease could be underestimated. Available meningococcal vaccines include polysaccharide vaccines and polysaccharide-protein conjugate vaccines against serogroups A, C, W and Y \[[@CR18]\]. Serogroup B vaccines are protein-based \[[@CR18]\].

This comprehensive narrative review was undertaken to collate and summarize published information on the epidemiology, disease burden and challenges in estimating the true burden of meningococcal disease in India. We also report broader vaccination recommendations for the prevention of meningococcal disease beyond outbreak settings and high-risk groups by summarizing data gathered from studies conducted in epidemic and endemic settings.

Figure [1](#Fig1){ref-type="fig"} elaborates on the findings in a form that could be shared with patients by healthcare professionals.

Methods {#Sec2}
=======

The literature search for this narrative review was conducted according to the Preferred Reporting Items for Systematic Literature Reviews and Meta-Analyses (PRISMA) guidelines \[[@CR19]\] to obtain relevant information using a reproducible, robust and transparent methodology. In line with these guidelines, we developed a search strategy and defined eligibility criteria prior to conducting the review. Searches were performed and retrieved publications were assessed for eligibility by two independent reviewers in a two-phase screening process based on the pre-defined eligibility criteria. Data were extracted from the final list of publications that were considered relevant for this review, the scope of data extraction was established a priori.

Search Sources and Strategy {#Sec3}
---------------------------

We searched the Medline (via PubMed) and Embase databases to identify peer-reviewed publications on meningococcal disease in India. The search strategy included both free-text and Emtree/MeSH terms such as "meningococcal infections," "meningococcus," "*N. meningitidis*" and "India" combined with Boolean operators (Table S1). National and regional World Health Organization (WHO) websites were also searched for information on vaccination recommendations; these searches were not systematically conducted.

Article Eligibility and Screening {#Sec4}
---------------------------------

Publications on meningococcal disease in India were considered eligible for inclusion based on the criteria provided in Table [1](#Tab1){ref-type="table"}. The screening process was limited to articles reported during the last 25 years (1994--2019). Eligible publications were based on: studies on meningococcal disease that focused on the disease burden and epidemiologic outcomes from observational studies, surveillance studies and case reports in India. Reference lists of reviews were consulted to identify additional original studies that may not have been captured by the search in Medline and Embase. Letters to the Editor were included if they contained original data on the disease burden and epidemiology of meningococcal disease in India.Table 1Inclusion and exclusion criteriaInclusion criteriaExclusion criteriaPopulationAll ages^a^Meningococcal disease caused by *Neisseria meningitidis*Any otherInterventionAll interventionsNoneOutcomeIncidenceNumber of casesAge-specific estimatesMortalityMorbidityClinical presentationCarriageOutcomes other than those covering epidemiology and burden of diseaseStudy designObservational studies (retrospective and prospective)Surveillance studies (active, passive)Case--control cohort studiesCase reportsPre-clinical and clinical studiesMeta-analysisLetters to the Editor^b^EditorialCommentary^b^Opinion paperReviews^c^Time limit25 years (January 1994--September 2019)Any otherLanguageEnglishAny other languageGeographic scopeIndiaAreas/countries other than in scope^a^Age group definitions are based on a position paper from the World Health Organization \[[@CR20]\]^b^Letters to the Editor and commentaries were included if they contained data that were not captured in other eligible publications retrieved from Medline and Embase^c^Reference lists of reviews were screened to identify publications of original studies that may not have been captured by the search in Medline and Embase

The publications retrieved from databases were screened by two independent researchers based on the eligibility criteria in two phases. The first phase included screening of titles and abstracts. The second phase consisted of reviewing the full-text publications. Any discrepancies in article inclusion were resolved through a discussion between the researchers.

Data Collection and Reporting {#Sec5}
-----------------------------

Data extracted from the eligible publications included contextual details (year, study design, geographic region etc.), information on the epidemiology of meningitis (incidence \[no. of cases, age-specific estimates, serogroups\]), morbidity (carriage, clinical presentation and sequelae) and mortality. Incidence rates are based on suspected cases as defined in the individual studies. Age groups such as neonate (0-30 days of age), pediatric (1 month--12 years of age), adolescent (12--18 years of age) and adult (\> 18 years of age) were defined according to the WHO pediatric age categories \[[@CR20]\]. We defined meningococcal meningitis according to the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM): a fulminant infection of the meninges and subarachnoid fluid by the bacterium *Neisseria meningitidis*, producing diffuse inflammation and peri-meningeal venous thromboses \[[@CR21]\]. While there is no ICD definition for meningococcal septicemia, sepsis was defined as life-threatening organ dysfunction caused by a dysregulated host response to infection \[[@CR22]\].

In this review, a descriptive overview of the epidemiology and burden of meningococcal disease in India is presented. Data from the individual studies are categorized into epidemic and endemic meningococcal disease settings, and case reports have been presented separately. Information on clinical characteristics is presented in a single section for studies reporting data from epidemic and endemic settings, and information on antibiotic resistance is presented in a similar manner (i.e., single section for both epidemic and endemic data). An overview of challenges in estimating the burden of meningococcal disease and the current status of meningococcal vaccination recommendations in India is presented.

Compliance with Ethics Guidelines {#Sec6}
---------------------------------

This article is based on previously conducted studies and does not contain any studies performed by any of the authors with human participants or animals.

Results {#Sec7}
=======

Overview of Included Studies {#Sec8}
----------------------------

A total of 262 publications were identified in the Medline and Embase databases (search cutoff date: August--September 2019). Excluding duplicates, 210 publications were screened based on their titles and abstracts; after excluding ineligible articles, 56 publications were further screened for eligibility based on full-text contents. Finally, 32 publications reporting data from original studies were included in this review \[[@CR16], [@CR23]--[@CR53]\] (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2PRISMA diagram.Template source: The PRISMA Statement \[[@CR19]\]

These 32 publications reported data on meningococcal disease from different regions of India: Delhi (*n* = 11) \[[@CR16], [@CR24]--[@CR26], [@CR34], [@CR40], [@CR45]--[@CR47], [@CR52], [@CR53]\], Karnataka (*n* = 5) \[[@CR36], [@CR43], [@CR44], [@CR49], [@CR50]\], Assam (*n* = 3) \[[@CR28], [@CR32], [@CR33]\], Kashmir (*n* = 2) \[[@CR27], [@CR41]\], Chandigarh (*n* = 2) \[[@CR37], [@CR51]\], Meghalaya (*n* = 2) \[[@CR30], [@CR31]\], multiple states (*n* = 2) \[[@CR38], [@CR39]\], Maharashtra (*n* = 1) \[[@CR29]\], Uttar Pradesh (*n* = 1) \[[@CR23]\], Odisha (*n* = 1) \[[@CR48]\], Tripura (*n* = 1) \[[@CR42]\] and Tamil Nadu (*n* = 1) \[[@CR35]\] (Table [2](#Tab2){ref-type="table"}).Table 2Meningococcal disease burden in India (*N* = 32) \[[@CR16], [@CR23]--[@CR53]\]AuthorStudy designStudy periodCarriage (no. and  %)State/region*N* (total no. enrolled)Population^a^Antibiotic resistance/decreased sensitivity*Epidemic disease*Dass Hazarika et al. 2013 \[[@CR30]\]Hospital-based (1 tertiary care centre), retrospectiveJanuary 2008--June 2009NRMeghalaya110 patients with invasive meningococcal diseasePediatric, adolescentCeftriaxoneMajumdar et al. 2011 \[[@CR42]\]^b^Hospital-basedJanuary--August 200922/69 (31.9%)Tripura146 CSF and serum samplesPediatric, adolescent, adultTetracyclineKushwaha et al. 2010 \[[@CR41]\]Observational epidemiologic study, prospectiveFebruary--May 200614/97 (14.4%)Kashmir2976 troopsAdultNRJhamb et al. 2009 \[[@CR39]\]Hospital-based (tertiary care center), retrospectiveApril 2005--December 2006NRDelhi (*n* = 94), Uttar Pradesh (*n* = 6)100 cases with meningococcal infectionPediatric, adolescentAmpicillin, erythromycinNair et al. 2009 \[[@CR45]\]Hospital-based (1 tertiary care center)April--July 2005 and January--March 2006NRDelhi380 clinically suspected casesPediatric, adolescent, adultPenicillin (15.4% of strains), levofloxacin (100% of strains), ofloxacin (84.6% of strains), ciprofloxacin (65.4% of strains), decreasing sensitivity to ceftriaxoneDuggal et al. 2007 \[[@CR34]\]Hospital-based (tertiary care center)December 2005--June 2006NRDelhi531 suspected cases of meningococcal meningitisPediatric, adolescent, adultDecreasing sensitivity to cotrimoxazoleArya et al. 2006 \[[@CR26]\]^b^Hospital-based (tertiary care center), retrospectiveMarch--April 2005NRDelhi2 (cases of meningococcal meningitis)AdultNo sensitivity to ciprofloxacin or cotrimoxazoleSaha et al. 2006 \[[@CR47]\]^b^Hospital-based (tertiary care center)From April 2005 (end period not defined)NRDelhi22 suspected cases of meningococcal diseasePediatric, adultNRSachdeva et al. 2005 \[[@CR16]\]Hospital-based, retrospective2002--2004NRDelhiNRNeonate (?), pediatric, adolescent, adultNR*Endemic disease*Jayaraman et al. 2018 \[[@CR38]\]Hospital-based (10 sentinel surveillance sites), prospectiveMarch 2012--February 2013NRTamil Nadu, Kerala, Karnataka, Odisha, Himachal Pradesh3104 clinically suspected cases of meningitisPediatricNRBali et al. 2017 \[[@CR27]\]National Institute-based, cross sectional, prospectiveAugust--September 20144/274 (1.5%)Jammu and Kashmir274 nasopharyngeal swabs of college freshmenAdultNRDevi et al. 2017 \[[@CR32]\]^b^Hospital-based (1 tertiary care center)January 2013--January 2015NRAssam303 CSF samples tested for pathogensNeonateNRBhagawati et al. 2014 \[[@CR28]\]Hospital-based (tertiary care center), prospectiveAugust 2009--July 2010NRAssam316 CSF samples from suspected cases of acute meningitisNeonate (?), pediatric, adolescent, adult50% sensitivity to penicillin G, amoxicillin-clavulanic acid, amikacin, ciprofloxacin, ceftriaxone, cefotaxime, ceftazidime, ImipenemFitzwater et al. 2013 \[[@CR35]\]Hospital-based (pediatric hospital), prospectiveJanuary 2008--September 2011NRTamil Nadu2564 suspected cases of meningitisPediatricNRGangane and Kumar 2013 \[[@CR36]\]Hospital-based (tertiary care center), prospectiveNovember 2010--December 2012NRKarnataka308 CSF samples from clinical cases of bacterial meningitis (including 82 with aerobic bacterial growth)Neonate (?), pediatric, adolescent, adult50% sensitivity to ampicillin, gentamicin, amikacinShameem et al. 2008 \[[@CR49]\]Hospital-based (tertiary care center), prospectiveFebruary 2003--January 2007NRKarnataka535 suspected cases of pyogenic meningitisPediatricTetracyclin, AmoxicillinKumar et al. 2008 \[[@CR40]\]Hospital-based (tertiary care center), prospectiveJanuary 2005--June 2007NRDelhi34 samples from suspected cases of meningococcal meningitisNeonates (?), pediatric, adolescent, adult8.8% resistance to penicillin, 5.9% to erythromycin and intermediate sensitivity to erythromycin (11.8%)Mani et al. 2007 \[[@CR43]\]Hospital-based (tertiary care center), retrospectiveJanuary 1996--December 2005NRKarnataka385 suspected cases of community acquired acute bacterial meningitisPediatric, adultNRShivaprakash et al. 2004 \[[@CR50]\]NRNRNRKarnataka204 clinically suspected acute pyogenic meningitisPediatricNRSinghi et al. 2004 \[[@CR51]\]Hospital-based (tertiary care center), retrospectiveJuly 1993--December 1996NRPunjab and Haryana220 children admitted with acute bacterial meningitis (among which88 children admitted to the intensive care unit)PediatricNRChinchankar et al. 2002 \[[@CR29]\]Hospital-based (tertiary care center), prospectiveApril 1997--March 1999NRMaharashtra54 cases of acute bacterial meningitisPediatricNR*Case reports*^c^Mutreja et al. 2018 \[[@CR44]\]Case report, retrospectiveNRNRKarnataka1 (military recruit)AdultNRGawalkar et al. 2017 \[[@CR37]\]Case report, retrospectiveNRNRPunjab and Haryana1AdolescentNRDevi et al. 2014 \[[@CR33]\]^b^Case report, retrospectiveNRNRAssam1NeonateNRAggarwal et al. 2013 \[[@CR25]\]Case report, retrospectiveNRNRDelhi1PediatricPenicillin, ciprofloxacinAbbas and Mujeeb 2013 \[[@CR23]\]Case report, retrospectiveNRNRUttar Pradesh1PediatricNRSahu et al. 2013 \[[@CR48]\]Case report, retrospectiveNRNROdisha1PediatricPenicillin, ampicillin, chloramphenicol, gentamicin, ciprofloxacinDass et al. 2013 \[[@CR31]\]Case report, retrospectiveNRNRMeghalaya1AdolescentNo response to azithromycin, vancomycin or ceftriaxoneVerma et al. 2011 \[[@CR53]\]Case report, retrospectiveNRNRDelhi1AdultNRAgarwal and Sharma 2010 \[[@CR24]\]Case report, retrospectiveNRNRDelhi1AdolescentNRPuri et al. 1995 \[[@CR46]\]Case report, retrospectiveNRNRDelhi1PediatricNRSuri et al. 1994 \[[@CR52]\]Case report, retrospectiveNRNRDelhi1PediatricNRAuthorAge (enrolled population unless specified)^a^IncidenceMortalitySerogroup distributionNo. of confirmed cases% of confirmed casesNo. of confirmed deaths% of confirmed deaths*Epidemic disease*Dass Hazarika et al. 2013 \[[@CR30]\]8.5 ± 5.1 years old (mean ± SD)68 (meningococcal meningitis) and 22 (meningococcemia) and 20 (both meningococcal meningitis and meningococcemia)24 confirmed (meningococcal meningitis) and 7 confirmed (meningococcemia) and 8 confirmed (both meningococcal meningitis and meningococcemia)61.8% (meningococcal meningitis) and 20.0% (meningococcemia) and 18.2% (both meningococcal meningitis and meningococcemia)35.3% (meningococcal meningitis) and 31.8% (meningococcemia) and 40.0% (both meningococcal meningitis and meningococcemia)2 (meningococcal meningitis) and 4 (meningococcemia) and 1 (both meningococcal meningitis and meningococcemia) Overall 7Mortality data not provided for confirmed cases (but for the sum of probable and confirmed cases)2.9% (meningococcal meningitis) and 18.2% (meningococcemia) and 5.0% (both meningococcal meningitis and meningococcemia) Overall 6.4%Mortality data not provided for confirmed cases therefore no  % reported for confirmed cases specificallyA (all cases)Majumdar et al. 2011 \[[@CR42]\]^b^From 2 months old to 60 years old (maximum reported cases in the age group 20--30 years old)28 (among all samples)19.2% (among all samples)NR (district-wise: 62 of 285 suspected or confirmed cases)NR (district-wise: 21.8%)A (all confirmed cases)Kushwaha et al. 2010 \[[@CR41]\]NR17 (14 with meningococcal meningitis and 3 with meningococcemia); 88.2% were 21--26 years old0.6% (of all troops)2 (of 17 confirmed cases; both with meningococcemia)11.8%A (all confirmed cases)Jhamb et al. 2009 \[[@CR39]\]\< 1 year old (no neonates): *n* = 5, 5--12 years old: *n* = 82100 (*n* = 67 for meningococcal meningitis, *n* = 20 for meningococcemia, *n* = 13 for both symptoms)100%17 (*n* = 3 for meningococcal meningitis, *n* = 5 for meningococcemia, *n* = 9 for both symptoms)17% (3.0% for meningococcal meningitis, 5.0% for meningococcemia, 9.0% for both symptoms)A (all culture-positive cases)Nair et al. 2009 \[[@CR45]\]Of 55 probable/confirmed cases: ≤ 5 years old: *n* = 3, 6--14 years old: *n* = 18, 15--29 years old: *n* = 25, 30--44 years old: *n* = 6, ≥ 45 years old: *n* = 33258.2% (of 55 probable/confirmed cases) and 8.4% (of 380 suspected cases)Present study: 8 (5 adults and 3 children)Overall: 62 of 444 meningococcal cases in April--July 2005 and 17 of 177 meningococcal cases in January--March 2006Present study: 14.5% (of 55 probable/confirmed) and 2.1% (of 380 suspected cases)Overall: 14.0% (of 444 meningococcal cases) in April--July 2005 and 9.6% (of 177 meningococcal cases) in January--March 2006A (all culture-positive cases)Duggal et al. 2007 \[[@CR34]\]3 months old to 65 years old;124 based on NICD definition (of 257 cases with microbial evidence of meningococcal infection; \< 1 year old: *n* = 6, 1--5 years old: *n* = 5, 6--14 years old: *n* = 51, 15--45 years old: *n* = 189, \> 45 years old: *n* = 6)23.4% (of 531 suspected cases) and 48.2% (of 257 cases with microbial evidence of meningococcal infection)15 (11 adults and 4 children; of 257 cases with microbial evidence of meningococcal infection)Overall: 60 of 441 cases in March--July 20055.8% (of 257 cases with microbial evidence of meningococcal infection)Overall: 13.6% (of 441 cases in March--July 2005)Of 195 CSF samples tested, 42 (21.5%) were identified as serogroup A and 63 (32.3%) as among serogroups ACYWArya et al. 2006 \[[@CR26]\]^b^25 years old2 (cases of meningococcal meningitis)100%00%A (both cases)Saha et al. 2006 \[[@CR47]\]^b^From 2.5 to 70 years old (10 suspected cases in the pediatric group and 12 in the adult group)1 (4.5 years old, culture confirmed)4.5%00%A (only one isolate tested)Sachdeva et al. 2005 \[[@CR16]\]For 258 cases reported: 0--5 years old: *n* = 27, 6--12 years old: *n* = 61, 13--20 years old: *n* = 71, 21--30 years old: *n* = 79, 31--40 years old: *n* = 12, 41--50 years old: *n* = 12, 50--75 years old: *n* = 8, \> 75 years old, *n* = 4Overall: 971NROverall: 118 (12.2% of 971 confirmed cases of meningococcal disease)NRNR*Endemic disease*Jayaraman et al. 2018 \[[@CR38]\]1 month old to 59 months old7 (of 257 confirmed cases of bacterial meningitis)2.7% (of 257 confirmed cases of bacterial meningitis) and \< 0.1% (of 3104 clinically suspected cases of meningitis)NRNRNRBali et al. 2017 \[[@CR27]\]\> 18 years oldNRNRNRNRB (all carriers)Devi et al. 2017 \[[@CR32]\]^b^\< 30 days old2 (of 62 CSF samples positive for pathogens)3.2% (of 62 CSF samples positive for pathogens) and \< 0.1% (of 303 CSF samples tested for pathogens)NRNRY (for at least one neonate, described in \[[@CR33]\]Bhagawati et al. 2014 \[[@CR28]\]0--10 years old: *n* = 163, 11--20 years old: *n* = 41, 21--70 years old: *n* = 111, \> 70 years old: *n* = 12 (of 44 culture-positive samples); \> 3 months old--10 years old: *n* = 1, \> 45 years old: *n* = 14.5% (of 44 culture-positive samples) and 0.6% (of 316 suspected cases of bacterial meningitis)NRNRNRFitzwater et al. 2013 \[[@CR35]\]\> 30 days old -- \< 24 months old (1--5 months old: 25%, 6--11 months old: 35%, 12--17 months old: 28%, 18--24 months old: 12%)2 (of 51 confirmed cases of bacterial meningitis)3.9% (of 51 confirmed cases of bacterial meningitis) and \< 0.1% (of 2564 suspected cases of meningitis)NRNRAmong serogroups A/Y (*n* = 1), among serogroups C/W (*n* = 1)Gangane and Kumar 2013 \[[@CR36]\]0--1 year old: *n* = 79, 1--5 years old: *n* = 50, 6--15 years old, *n* = 39, 16--60 years old: *n* = 129, \> 60 years old: *n* = 112 (of 82 with aerobic bacterial growth)2.4% (of 82 with aerobic bacterial growth) and \< 0.1% (of 308 CSF samples from clinical cases of bacterial meningitis)NRNRNRShameem et al. 2008 \[[@CR49]\]Most cases: \> 30 days old--3 years old18 (of 236 untreated cases of pyogenic meningitis)7.6% (of 236 untreated cases of pyogenic meningitis) and 3.4% (of 535 suspected cases of pyogenic meningitis)NRNRNRKumar et al. 2008 \[[@CR40]\]0--10 years old: *n* = 9, 11--20 years old: *n* = 8, 21--30 years old: *n* = 12, 31--40 years old, *n* = 3, 41--50 years old: *n* = 1, 51--60 years old, *n* = 134100% (of 34 samples from suspected cases of meningococcal meningitis)NRNRA (all samples)Mani et al. 2007 \[[@CR43]\]\< 12 years old: *n* = 51, adults: *n* = 3344 (all adults)1.0% (of 385 suspected cases of community acquired acute bacterial meningitis)NRNRNRShivaprakash et al. 2004 \[[@CR50]\]NR27.4% (of 27 culture-positive samples) and 1.0% (of 204 CSF samples)NRNRNRSinghi et al. 2004 \[[@CR51]\]\< 1 year old: *n* = 49, 1--5 years old: *n* = 26, 5--12 years old, *n* = 13 (of 88 children admitted to the intensive care unit)11.1% (of 88 children admitted to the intensive care unit) and 0.5% (of 220 children admitted with acute bacterial meningitis)NRNRNRChinchankar et al. 2002 \[[@CR29]\]From 1 month old to 5 years old (42 cases \< 1 year old)11.9% (of 54 cases of acute bacterial meningitis)NRNRNR*Case reports*^c^Mutreja et al. 2018 \[[@CR44]\]21 years old1 (case of meningococcemia)100%1100%NRGawalkar et al. 2017 \[[@CR37]\]17 years old1 (case of meningococcemia)100%00%NRDevi et al. 2014 \[[@CR33]\]^b^38 weeks old gestation male baby, 14 days old1100%00%YAggarwal et al. 2013 \[[@CR25]\]1 year old1100%00%BAbbas and Mujeeb 2013 \[[@CR23]\]6 months old1100%00%NRSahu et al. 2013 \[[@CR48]\]11 years old1 (septic arthritis)100%00%Among serogroups A-DDass et al. 2013 \[[@CR31]\]13 years old1 (polyarthritis)100%00%NRVerma et al. 2011 \[[@CR53]\]19 years old1100%00%NRAgarwal and Sharma 2010 \[[@CR24]\]15 years old1100%00%APuri et al. 1995 \[[@CR46]\]11 years old1 (Guillain-Barré syndrome possibly caused by meningococcal infection)100%00%NRSuri et al. 1994 \[[@CR52]\]4 months old1100%1100%B*AB* antibiotics, *Adolescent* 12--18 years of age, *Adult* ≥ 18 years of age, *CSF* cerebrospinal fluid, *N* total number of subjects, *n* number of subjects, *Neonate* 0--30 days of age, *NICD* National Institute of Communicable Diseases, *no*. number, *NR* not reported, *Pediatric* 1 month of age up to 12 years of age, *SD* standard deviation^a^Age group definitions are based on a position paper from the World Health Organization \[[@CR20]\]^b^Letters to editors were included if they contained data from outbreaks that were not captured through other publications^c^Assumed to present cases of endemic infection encountered in the same region as that of the hospital where the patient presented

The majority of publications reported data on endemic meningococcal disease (*n* = 23) \[[@CR23]--[@CR25], [@CR27]--[@CR29], [@CR31]--[@CR33], [@CR35]--[@CR38], [@CR40], [@CR43], [@CR44], [@CR46], [@CR48]--[@CR53]\]. Of these 23 publications, 11 were case reports \[[@CR23]--[@CR25], [@CR31], [@CR33], [@CR37], [@CR44], [@CR46], [@CR48], [@CR52], [@CR53]\]. Lastly, 9 publications of the 32 reported data on meningococcal disease in epidemic settings \[[@CR16], [@CR26], [@CR30], [@CR34], [@CR39], [@CR41], [@CR42], [@CR45], [@CR47]\] (Table [2](#Tab2){ref-type="table"}).

Excluding the 11 case reports, a total of 20 publications reported disease epidemiology from either retrospective or prospective studies \[[@CR16], [@CR26]--[@CR30], [@CR32], [@CR34]--[@CR36], [@CR38]--[@CR43], [@CR45], [@CR47], [@CR49], [@CR51]\]. The study design was not reported for one publication \[[@CR50]\] (Table [2](#Tab2){ref-type="table"}).

An equal number of publications reported data for the pediatric population (*n* = 11) \[[@CR23], [@CR25], [@CR29], [@CR35], [@CR38], [@CR46], [@CR48]--[@CR52]\] and mixed populations of different age groups including neonatal, pediatric, adolescent and adult, respectively \[[@CR16], [@CR28], [@CR30], [@CR34], [@CR36], [@CR39], [@CR40], [@CR42], [@CR43], [@CR45], [@CR47]\]. A few publications reported data specifically for adult (*n* = 5) \[[@CR26], [@CR27], [@CR41], [@CR44], [@CR53]\], adolescent (*n* = 3) \[[@CR24], [@CR31], [@CR37]\] and neonatal (*n* = 2) \[[@CR32], [@CR33]\] populations, respectively (Table [2](#Tab2){ref-type="table"}).

Epidemic Meningococcal Disease in India {#Sec9}
---------------------------------------

### Overall Incidence and Mortality {#Sec10}

In this review, we identified nine publications that reported incidence and mortality data in outbreak settings in India since 2002 \[[@CR16], [@CR26], [@CR30], [@CR34], [@CR39], [@CR41], [@CR42], [@CR45], [@CR47]\]. Seven of these nine publications provided the proportion of confirmed cases of *N. meningitidis* \[[@CR26], [@CR30], [@CR34], [@CR39], [@CR41], [@CR42], [@CR45], [@CR47]\] (Table [2](#Tab2){ref-type="table"}). Of suspected cases, confirmed *N. meningitidis* infection concerned 4.5--23.4% \[[@CR34], [@CR42], [@CR45], [@CR47]\].

The mortality rate due to *N. meningitidis* was reported in nine publications (0.0--21.8% of confirmed cases) \[[@CR16], [@CR26], [@CR30], [@CR34], [@CR39], [@CR41], [@CR42], [@CR45], [@CR47]\]. No deaths were reported in two studies \[[@CR26], [@CR47]\] (Table [2](#Tab2){ref-type="table"}).

### Age- and Serogroup-Specific Distribution {#Sec11}

The age-specific disease burden of *N. meningitidis* cases in outbreak settings was reported in eight publications and included age groups \< 2 months of age to \> 75 years of age \[[@CR16], [@CR26], [@CR30], [@CR34], [@CR39], [@CR42], [@CR45], [@CR47]\]. Notably, an increase was reported in the number of cases among adolescents and adults, which may indicate a shift in the mean age of cases during outbreaks \[[@CR16], [@CR26], [@CR34], [@CR39], [@CR42], [@CR45]\] (Table [2](#Tab2){ref-type="table"}).

Serogroup-specific disease burden was reported in eight publications \[[@CR26], [@CR30], [@CR34], [@CR39], [@CR41], [@CR42], [@CR45], [@CR47]\]. The majority of these publications reported the prevalence of serogroup A-specific disease (*n* = 7) \[[@CR26], [@CR30], [@CR39], [@CR41], [@CR42], [@CR45], [@CR47]\]. In one publication, of the cerebrospinal fluid samples tested, roughly 20% were positive for serogroup A and 30% for serogroups A, C, W and Y (specific serogroup was not reported in the study) \[[@CR34]\] (Table [2](#Tab2){ref-type="table"}).

Endemic Meningococcal Disease in India {#Sec12}
--------------------------------------

### Overall Incidence and Mortality {#Sec13}

Twelve publications presented data from non-outbreak settings in India, which reported cases mostly from regions that did not usually have outbreaks. Most publications reported percentages of confirmed cases in the range of 0.1 (*n* = 2)--7.6% (*n* = 18) \[[@CR28], [@CR29], [@CR32], [@CR35], [@CR36], [@CR38], [@CR43], [@CR49]--[@CR51]\] of suspected cases, and in one publication from Delhi, 71.4--100% (*n* = 34) of the samples were positive for *N.meningitidis*, depending on the technique used for diagnosis \[[@CR40]\]. Mortality was not reported in any of these publications (Table [2](#Tab2){ref-type="table"}).

### Age- and Serogroup-Specific Distribution {#Sec14}

Eight publications provided information on the age-specific distribution of endemic cases \[[@CR28], [@CR29], [@CR35], [@CR36], [@CR40], [@CR43], [@CR49], [@CR51]\]. Three of those eight publications, having enrolled pediatric, adolescent and adult populations, show that adults and adolescents can represent half or more of the cases of meningococcal disease \[[@CR28], [@CR40], [@CR43]\] (Table [2](#Tab2){ref-type="table"}). Four publications presented specific serogroup information in non-outbreak settings where serogroups A, B, A/Y (specific serogroup was not reported in the study), C/W (specific serogroup was not reported in the study) and Y were reported \[[@CR27], [@CR32], [@CR35], [@CR40]\] (Table [2](#Tab2){ref-type="table"}).

### Clinical Characteristics {#Sec15}

As shown in Table S2, a broad spectrum of clinical presentations associated with *N. meningitidis* was reported in studies from outbreak settings in India \[[@CR16], [@CR26], [@CR30], [@CR34], [@CR39], [@CR41], [@CR42], [@CR45]\]. The preponderant clinical features of meningococcal disease are fever, headache, neck stiffness, vomiting, altered sensorium and bulging anterior fontanelle (specifically in infants). Complications such as raised intracranial pressure, coagulopathy, hepatopathy, arthritis and gangrene have also been reported. Purpura fulminans is present in cases of meningococcemia \[[@CR26], [@CR30], [@CR34], [@CR39], [@CR41], [@CR42], [@CR45]\]. Two publications from outbreak settings reported that overcrowding was a risk factor for the carriage and transmission of *N. meningitidis* \[[@CR16], [@CR41]\].

Clinical presentations of suspected meningitis in non-outbreak settings included fever, headache, neck stiffness, vomiting, altered sensorium and bulging anterior fontanelle (specifically in infants) \[[@CR28], [@CR29], [@CR32], [@CR35], [@CR38], [@CR51]\]. We identified one publication with information on serogroup B carriage in a non-outbreak setting \[[@CR27]\]. In this single-center study, nasal carriage of *N. meningitidis* (serogroup B) was found in about 1.5% of the new college hostel residents \[[@CR27]\]. Close proximity among the hostellers was reported as the likely risk factor in disease transmission \[[@CR27]\] (Table S2).

### Antibiotic Sensitivity and Resistance {#Sec16}

Six publications \[[@CR26], [@CR30], [@CR34], [@CR39], [@CR42], [@CR45]\] describing studies in epidemic settings and four surveillance studies in endemic settings provided information on antibiotic sensitivity and resistance \[[@CR28], [@CR36], [@CR40], [@CR49]\]. The majority of these studies show sensitivity to penicillin, ampicillin, ceftriaxone, cefotaxime, erythromycin, azithromycin and chloramphenicol.

In one study, resistance to quinolones was considered high for levofloxacin, ofloxacin and ciprofloxacin. MIC90 (minimum inhibitory concentration to inhibit the growth of 90% of organisms) for ciprofloxacin and levofloxacin was 0.19 mg/ml and ofloxacin 0.5 mg/ml, all in the resistant range \[[@CR45]\]. Resistance/intermediate sensitivity to ciprofloxacin was also found in two other studies \[[@CR26], [@CR42]\]. Some isolates with penicillin resistance/intermediate sensitivity were found in one study. In this publication, all patients with penicillin-resistant organisms or intermediate sensitivity succumbed to the disease \[[@CR45]\]. In another study good clinical response to ceftriaxone was found in the beginning of the outbreak but increasingly poor response to it after 6 months \[[@CR30]\]. One publication also reported reduced sensitivity to cotrimoxazole \[[@CR34]\]. Jhamb et al. reported that the majority of isolates were sensitive to penicillin/ampicillin, ceftriaxone, chloromycetin, ciprofloxacin and erythromycin; only one isolate each was resistant to ampicillin and erythromycin \[[@CR39]\].

Similar results of decreased antibiotic sensitivity were reported in four surveillance studies in endemic settings for amoxicillin, ampicillin, erythromycin and penicillins \[[@CR28], [@CR36], [@CR40], [@CR49]\].

Case Reports {#Sec17}
------------

### Overview of Case Reports {#Sec18}

A total of 11 case reports were included in this review, and all of these presumably reported clinical findings from non-outbreak settings \[[@CR23]--[@CR25], [@CR31], [@CR33], [@CR37], [@CR44], [@CR46], [@CR48], [@CR52], [@CR53]\]. Case reports from Delhi (*n* = 5) \[[@CR24], [@CR25], [@CR46], [@CR52], [@CR53]\], Karnataka (*n* = 1) \[[@CR44]\], Punjab and Haryana (*n* = 1) \[[@CR37]\], Assam (*n* = 1) \[[@CR33]\], Uttar Pradesh (*n* = 1) \[[@CR23]\], Odisha (*n* = 1) \[[@CR48]\] and Meghalaya (*n* = 1) \[[@CR31]\] were reported.

### Age- and Serogroup-Specific Distribution {#Sec19}

Case reports covered the pediatric (*n* = 5) \[[@CR23], [@CR25], [@CR46], [@CR48], [@CR52]\], adolescent (*n* = 3) \[[@CR24], [@CR31], [@CR37]\], adult (*n* = 2) \[[@CR44], [@CR53]\] and neonatal (*n* = 1) \[[@CR33]\] populations with ages ranging between 14 days and 21 years (Table [2](#Tab2){ref-type="table"}).

Serogroup data were documented in five case reports \[[@CR24], [@CR25], [@CR33], [@CR48], [@CR52]\] among which serogroup A, A-D (specific serogroup was not reported in the study) (*n* = 2) \[[@CR24], [@CR48]\] and the less common serogroups B and Y (*n* = 3) \[[@CR25], [@CR33], [@CR52]\] were reported.

### Clinical Characteristics {#Sec20}

As shown in Table S2, clinical presentations included symptoms such as fever, headache, neck stiffness, purpuric rash and rarer symptoms perhaps reflecting complex immune reactions, such as joint pains, myocarditis, wheeze and crepitation in the left lower chest \[[@CR31], [@CR37], [@CR44], [@CR48], [@CR53]\]. However, it is not uncommon that meningococci are isolated (culture) from such sites \[[@CR54], [@CR55]\].

In another case report, Guillain-Barré syndrome following meningococcal infection was reported, but a causal relationship with the meningococcal infection is not clear \[[@CR46]\]. Complications included auto-amputation of toes and fingers and hypotonia \[[@CR23]--[@CR25], [@CR46]\].

### Antibiotic Sensitivity and Resistance {#Sec21}

Antibiotic resistance was reported in two case reports for ampicillin, chloramphenicol, ciprofloxacin, gentamicin and penicillin \[[@CR25], [@CR48]\] (Table [2](#Tab2){ref-type="table"}).

Challenges in Estimating Meningococcal Disease Burden {#Sec22}
-----------------------------------------------------

Meningococcal disease appears to be a notifiable disease in India, even though reporting is not mandatory \[[@CR15], [@CR56], [@CR57]\]. Therefore, challenges in estimating the true burden of meningococcal disease are compounded. Detection of disease using gold standard bacterial culture methods for meningococcal diagnosis are too slow and frequently compromised by prior antibiotic treatment. In India, the widespread availability of antibiotics and initiation of treatment prior to sample collection are known to contribute to the increasing number of negative cultures, which impede case detection and confirmation \[[@CR56]\]. While other techniques are used, quality control is generally lacking---different methods are used with varying specificities and sensitivities for *N. meningitidis*.

A previous review from India suggests that the meningococcal disease burden in India is not reliably known because of suboptimal surveillance and a poor level of support for microbiologic diagnosis \[[@CR15], [@CR56]\]. We found 23 publications reporting endemic meningococcal disease, 11 of which were case reports presumably not linked to outbreaks, suggesting that endemic meningococcal disease could indeed be severely under-reported and therefore under-recognized \[[@CR23]--[@CR25], [@CR27]--[@CR29], [@CR31]--[@CR33], [@CR35]--[@CR38], [@CR40], [@CR43], [@CR44], [@CR46], [@CR48]--[@CR53]\].

Recommendations on Meningococcal Vaccination {#Sec23}
--------------------------------------------

According to the WHO, countries with high (\> 10 cases/100,000 population/year) or moderate endemic rates (2--10 cases/100,000 population/year) of meningococcal disease and countries with frequent outbreaks should introduce large scale meningococcal vaccination programs. The vaccine may be administered through National Immunization Programs while supplementary immunization activities may be conducted during epidemics. Depending on the national epidemiology and availability of healthcare resources, countries should implement the most appropriate control policy. In countries where the disease occurs less frequently (\< 2 cases/100,000 population/year), the WHO recommends meningococcal vaccination for high-risk groups, such as children and young adults residing in closed communities, e.g., boarding schools or military camps. Laboratory workers at risk of exposure to meningococci and travelers to high-endemic areas should also be vaccinated. According to the WHO, meningococcal vaccination should also be offered to all individuals suffering from immunodeficiencies \[[@CR18]\].

Not many countries---but a growing number---have included vaccination against meningococcal disease (such as the quadrivalent MenACWY vaccine; Table [3](#Tab3){ref-type="table"}) in their immunization programs. Countries adapt their vaccination recommendations based on local information about epidemiology, risk groups, disease burden, cost-effectiveness and vaccine impact studies but these data are lacking in most countries. In India, meningococcal vaccination with MenACWY is recommended only for certain high-risk groups of children, during outbreaks and for international travelers, including students going abroad to pursue studies and travelers to the Hajj and sub-Saharan Africa regions \[[@CR17], [@CR58]\]. There are no recommendations for meningococcal B vaccination for high-risk groups such as travelers.Table 3National immunization programs/clinical recommendations for routine child-adolescent quadrivalent (A, C, W, Y) meningococcal vaccination from few key countriesCountry^a^Vaccination scheduleChile \[[@CR63]\]12 months old: 1 doseArgentina \[[@CR64]\]3 doses at 3, 5 and 15 (booster) months of age11 years old: 1 doseUK \[[@CR65]\]14 years old: 1 doseAustralia \[[@CR66]\]12 months old: 1 dose14--16 years old: 1 dose (15--19 years old for catch-up)The Netherlands \[[@CR67]\]14 months old: 1 dose14 years old: 1 doseSpain \[[@CR68]\]12 years old: 1 dose (13--18 years old for catch-up)Switzerland \[[@CR69]\]2 years old: 1 dose11--15 years old: 1 doseAustria \[[@CR70]\]11--13 years old: 1 dose (14--18 years old for catch-up)Canada \[[@CR71]\]12--24 years old: 1 dose of either Men C or Men ACWYGreece \[[@CR72]\]11--12 years old: 1 dose (13--18 years old for catch up)Italy \[[@CR73]\]12--14 years old: 1 doseSaudi Arabia \[[@CR74]\]2 doses at 9 and 12 months of age18 years old: 1 doseUSA \[[@CR75]\]2 doses at 11--12 and 16 years of age (13--15 and/or 16--18 years old for catch-up)Belgium \[[@CR76]\]At 15 months and 15--16 years^a^Countries where MenACWY vaccination is in place for specific groups or under specific circumstances (i.e., outbreaks): Czech Republic, Greece, Mauritius, Bahamas, Colombia, Guyana, Panama, Paraguay, Suriname, Trinidad and Tobago, Egypt, Iran, Oman, Qatar, United Arab Emirates, Armenia, Israel, Russian Federation, Serbia, Slovenia, Maldives, Brunei Darussalam, Malaysia, New Zealand \[[@CR77]\]

Discussion {#Sec24}
==========

We conducted a comprehensive review of the literature to provide an overview of the epidemiology and burden of meningococcal disease in India. The findings from the 32 eligible publications are in line with observations from previous reviews conducted with the same geographic scope of India \[[@CR13], [@CR15]\]. Regardless of age or study design, *N. meningitidis* is found in 4.5--23.4% \[[@CR34], [@CR42], [@CR45], [@CR47]\] and 0.1--7.6% \[[@CR28], [@CR29], [@CR32], [@CR35], [@CR36], [@CR38], [@CR43], [@CR49]--[@CR51]\] of suspected meningitis cases in outbreak and non-outbreak settings, respectively. The wide range of disease burden estimates can be explained by differences in study design and setting. In addition, patient age, clinical presentation and confirmation of diagnosis are primary factors that influence estimates of incidence, occurrence of complications and deaths due to meningococcal disease in India. This review reveals that meningococcal disease is not limited only to the pediatric population, but that adolescents and adults are also affected, as previously shown \[[@CR13]\]. Adolescents and adults are also known to play a significant role in carriage, especially those living in crowded conditions \[[@CR27], [@CR41]\]. Serogroup A disease is identified as the predominant strain during outbreaks in India \[[@CR26], [@CR30], [@CR39], [@CR41], [@CR42], [@CR45], [@CR47]\], but other serogroups (B, C, Y and W) are also documented in endemic settings \[[@CR25], [@CR27], [@CR32], [@CR33], [@CR35], [@CR52]\]. These observations are consistent with findings from Asia and the Pacific region, which show that serogroup A disease is most prominent in low-income countries such as the Philippines, while other countries like China, Taiwan, Japan and Korea have documented a mixed epidemiology of serogroups A, B, C and W \[[@CR14]\].

In this review, 23 publications from non-outbreak settings are reported, 11 of which are case reports of individual patients \[[@CR23]--[@CR25], [@CR27]--[@CR29], [@CR31]--[@CR33], [@CR35]--[@CR38], [@CR40], [@CR43], [@CR44], [@CR46], [@CR48]--[@CR53]\]. The reporting of the disease burden estimates from non-outbreak settings might therefore be skewed in their presentation of the true disease burden. A previous review states that the burden of endemic meningococcal disease in India is difficult to quantify \[[@CR56]\]. Low bacterial detection rates in many studies, considered to be the result of both technical laboratory aspects and high levels of antibiotic use, have prevented the provision of true disease burden estimates in India \[[@CR56]\].

In the case of meningococcal disease caused by *N. meningitidis*, immediate initiation of parenteral antibiotics, preferably within half an hour after hospital admission or diagnosis, remains the mainstay of treatment. Rapid initiation of antibiotic therapy is known to prevent foreseen complications such as septic shock, raised intracranial pressure and mortality. However, indiscriminate use of antibiotics has led to reduced antibiotic sensitivity and antibiotic-resistant strains of bacteria as reported in several studies in outbreak and non-outbreak settings \[[@CR25], [@CR26], [@CR28], [@CR30], [@CR31], [@CR36], [@CR39], [@CR40], [@CR42], [@CR45], [@CR48], [@CR49]\]. These disadvantages of using antibiotics suggest that a better approach to reducing the disease burden and tackling high mortality rates due to meningococcal infections is through vaccination \[[@CR3], [@CR18]\].

Given the perceived low incidence of meningococcal disease, meningococcal vaccination is not routinely administered in India. The Indian Academy of Pediatrics (IAP) recommends meningococcal vaccination only for certain high-risk groups of children such as those with congenital or acquired immunodeficiency, during outbreaks, for international travelers such as students studying abroad and travelers to Hajj and sub-Saharan Africa and for household contacts \[[@CR15], [@CR17]\]. The IAP also recommends conjugate vaccines rather than polysaccharide meningococcal vaccines \[[@CR17]\]. This is because polysaccharide vaccines are associated with immunologic shortcomings, such as poor immunogenicity in children \< 2 years of age, inability to generate immune memory and provision of only transient and incomplete protection against carriage. For these reasons, polysaccharide vaccines do not substantially contribute to herd immunity and induce hyporesponsiveness \[[@CR17], [@CR18]\]. Lastly, vaccines for serogroup B could be beneficial for travelers going to areas with high or intermediate endemicity of meningitis.

Designing the most effective vaccination strategy for a particular country or setting is best guided by robust epidemiologic data, especially to detect outbreaks and to determine the need for vaccination. While the IDSP conducts routine disease surveillance within the country, the corresponding data are not part of the public domain \[[@CR57]\]. The available data provided by the National Health Statistics present a high rate of meningococcal disease incidence, which cannot be confirmed independently \[[@CR59]--[@CR61]\]. These findings are in line with the situation analyzed for Asia and the Pacific region, which indicates that meningococcal disease is under-reported in this region \[[@CR14]\]. The review of Sinclair et al., specific to India, shows that, despite incomplete reporting, meningococcal meningitis has been a notifiable disease in India over the past decades and that the country is susceptible to outbreaks \[[@CR13]\]. As robust epidemiologic data on meningococcal disease in India are lacking, reliable longitudinal surveillance systems are urgently needed to characterize meningococcal disease epidemiology, including a standard clinical case definition, field investigation of cases and outbreaks, and laboratory capacity for the confirmation and characterization of *N. meningitidis* serogroups. In addition, the continued surveillance of meningococcal disease including developing resistance patterns in *N. meningitidis* should dictate the need and timing of repeat mass vaccination campaigns.

Limitations and Future Research {#Sec25}
===============================

This narrative review has several limitations related to the methodology such as the exclusion of gray literature sources (i.e., literature not peer-reviewed prior to publication such as government databases and reports) in the systematic search, conducted in Medline and Embase. As we aimed to obtain a better understanding of published epidemiology and disease burden data, broadening our search to other sources and having a risk-of-bias analysis was not deemed necessary.

Generalizability of the results from this review should be done cautiously as incidence rates were presented based on suspected cases as defined by the individual studies and case reports. Furthermore, not all articles provide adequate data regarding methods used for microbiologic diagnosis and serogroup analysis.

Barriers to eliciting the true disease burden of meningococcal disease include factors related to a lack of reporting in the individual studies driven by suboptimal surveillance infrastructure and insufficient diagnostic facilities. The application of sensitive quantitative polymerase chain reaction assays \[[@CR62]\] can prove useful in epidemiologic studies to improve knowledge of the true burden of meningococcal disease in India. Also, the true estimate of antibiotic resistance is lacking as not all data are available for each publication and as such treatment modalities are not discussed. Research into the use of advanced, more discriminate diagnostics methods, such as multilocus sequence typing and microscopic agglutination test, may provide information on the clonal dispersion of reported cases in India, including antibiotic resistance. However, logistical and financial considerations have to be taken into account to evaluate the feasibility of large-scale implementation of such methods for disease surveillance in India.

Conclusion {#Sec26}
==========

Meningococcal disease surveillance in India is not routine and data on endemic disease remain insufficient. Occasional outbreaks of meningococcal disease have been documented in India affecting adolescents and young adults in addition to the pediatric population. The endemic meningococcal disease burden in India is underestimated because of the suboptimal surveillance infrastructure. To this end, the establishment of routine surveillance for bacterial meningitis and standardizing protocols for laboratory diagnosis demand urgent attention.

Despite the availability of safe and effective meningococcal vaccines, routine meningococcal vaccination is not recommended in India. Given the recommendation from the IAP, the use of meningococcal conjugate vaccines could contain future epidemics of meningococcal disease if detected early through improved surveillance. In addition, the routine immunization of high-risk individuals as well as adolescents and adults involved in carriage and transmission of the disease could be beneficial to prevent the occurrence of outbreaks.
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